Phibro Animal Health (PAHC)
(Delayed Data from NSDQ)
$17.07 USD
+0.31 (1.85%)
Updated May 3, 2024 04:00 PM ET
After-Market: $17.05 -0.02 (-0.12%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.07 USD
+0.31 (1.85%)
Updated May 3, 2024 04:00 PM ET
After-Market: $17.05 -0.02 (-0.12%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Zacks News
Should You Sell Phibro Animal Health (PAHC) Before Earnings?
by Zacks Equity Research
Given that Phibro Animal Health (PAHC) has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings.
Phibro (PAHC) Strong on Animal Health Arm, Dull MFA Ails
by Zacks Equity Research
Phibro's (PAHC) Animal Health segment has been a key contributor to growth over the last few quarters. MFA remains soft in the United States due to sales decline of medically important antimicrobials.
Dull MFA & Mineral Nutrition Sales Hurt Phirbo, Rivalry Rife
by Zacks Equity Research
Phibro's (PAHC) Medicated feed additives (MFA) business was weak in the United States. Also, a persistent decline in Mineral Nutrition segment sales is likely to raise concern.
Phibro Animal (PAHC) Beats on Q1 Earnings, Reiterates View
by Zacks Equity Research
Phibro Animal (PAHC) witnesses year-over-year improvement across all segments in Q1.
Phibro Animal Banks on Diverse Portfolio, Competition Rife
by Zacks Equity Research
Phibro Animal (PAHC) is consistently trying to expand its product portfolio to counter the tough competition in the animal health space.
Phibro (PAHC) Down 2.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phibro Animal Health Expands Globally Amid Tough Competition
by Zacks Equity Research
Phibro (PAHC) is consistently trying to expand globally to counter the tough competition in the animal health and mineral nutrition space.
Phibro Animal (PAHC) Beats Q4 Earnings & Sales Estimates
by Zacks Equity Research
Phibro Animal (PAHC) reported solid fourth-quarter fiscal 2017 revenues on the back of sales growth in the Animal Health, Mineral Nutrition and Performance Products segments.
Phibro Animal Health & Zydus Cadila Plan to Expand in India
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) recently announced plans to enter into a long-term agreement with global pharmaceutical company Zydus Cadila to expand in the rapidly growing poultry market in India.
Health Care Battle Rages On: 2 MedTech Stocks to Buy
by Zacks Equity Research
Let's focus on two MedTech Stocks which are fundamentally strong amidst the volatile market condition.
Here's Why Phibro Animal Health Is Worth Buying Right Now
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC), has rallied 24.2% over the past three months, ahead of the S&P 500's mere 2.6% gain.
Phibro Animal Health (PAHC) Rides High on Solid Prospects
by Zacks Equity Research
On Jun 12, we issued an updated research report on NJ-based Phibro Animal Health Corporation (PAHC) ??? a leading global diversified animal health and mineral nutrition company.
Phibro Animal Health (PAHC) Up 10% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Phibro Animal Health (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can The Uptrend Continue for Phibro Animal Health (PAHC)?
by Zacks Equity Research
Investors certainly have to be happy with Phibro Animal Health Corp (PAHC) and its short term performance
Phibro (PAHC) Posts In Line Earnings in Q3, Revises View
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 37 cents in the third quarter of fiscal 2017, down 7.5% year over year.
Why Is Phibro (PAHC) Down 7% Since the Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Phirbo Animal (PAHC) Tops Q2 Earnings, Reaffirms FY17 View
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 39 cents in the second quarter of fiscal 2017.
Medical Product Stocks' Earnings on Feb 6: HAE, PAHC & More
by Zacks Equity Research
Let's take a look at the major Medical products stocks slated to release their quarterly reports on Feb 6.